Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Jun 28;17(6):e1009445. doi: 10.1371/journal.ppat.1009445

Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition

Mamun Kabir 1, Masud Alam 1, Uma Nayak 2,3, Tuhinur Arju 1, Biplob Hossain 1, Rubaiya Tarannum 1, Amena Khatun 1, Jennifer A White 4, Jennie Z Ma 2,4, Rashidul Haque 1, William A Petri Jr 4,5,6,*, Carol A Gilchrist 4
Editor: Kami Kim7
PMCID: PMC8270466  PMID: 34181697

Abstract

We conducted a longitudinal study of cryptosporidiosis from birth to three years of age in an urban slum of Dhaka Bangladesh. Fecal DNA was extracted from monthly surveillance samples and diarrheal stool samples collected from 392 infants from birth to three years. A pan-Cryptosporidium qPCR assay was used to identify sub-clinical and symptomatic cryptosporidiosis. Anthropometric measurements were collected quarterly to assess child nutritional status. 31% (121/392) of children experienced a single and 57% (222/392) multiple infections with Cryptosporidium. Repeat infections had a lower burden of parasites in the stool (Cq slope = -1.85; p<0.0001) and were more likely to be sub-clinical (Chi square test for trend; p = 0.01). Repeat infections were associated with the development of growth faltering (Pearson correlation = -0.18; p = 0.0004). High levels of fecal IgA antibodies against the Cryptosporidium Cp23 sporozoite protein at one year of life were associated with a delay in reinfection and amelioration of growth faltering through three years of life (HAZ IgA high responders -1.323 ± 0.932 versus HAZ -1.731 ± 0.984 p = 0.0001). We concluded that nonsterile immunity to cryptosporidiosis in young children was associated with high levels of mucosal IgA anti-Cp23 and protection from diarrhea and growth faltering.

Trial Registration: NCT02764918.

Author summary

Cryptosporidium is one of the top causes of diarrhea and growth faltering in Bangladesh infants. We discovered that a prior infection resulted in incomplete immunity that protected from diarrhea and growth faltering but not infection and was associated with mucosal IgA against a sporozoite surface protein Cp23. The most important implication of these findings is that a cryptosporidiosis vaccine may not need to achieve complete protection from infection to have a beneficial impact on child health.

Introduction

Cryptosporidium spp. parasites are leading causes of diarrheal disease in infants living in low and middle income countries [14]. They are additionally a cause of water-borne outbreaks of diarrhea in high income countries and of chronic diarrhea in people living with HIV infection [5]. There is no vaccine and development will require an understanding of the natural history of cryptosporidiosis [3,612]. To this end, a community-based prospective cohort study of cryptosporidiosis was begun in 2014 [13]. The study subjects, born in an urban slum in Dhaka, Bangladesh were enrolled during the first week of life [1315]. In humans and in animal models vaccination or prior infection resulted in partial protection against reinfection [1619]. For example we observed that high fecal IgA against the sporozoite protein Cp23 delayed but did not prevent a repeat infection with Cryptosporidium spp. [20]. Ajjampur et al observed a decrease in the incidence of diarrhea in reinfected children [21]. In contrast Kattula et al found that while the reinfection frequency was decreased the proportion of symptomatic disease was unchanged [9]. In human volunteer studies second infections were associated with reduced parasite burden and less severe diarrhea [22].

In addition to diarrheal disease cryptosporidiosis is associated with development of malnutrition [8,2326]. Here we report the natural history of cryptosporidiosis from a longitudinal study of urban slum children from birth through three years of age in Dhaka, Bangladesh, demonstrating that immunity is characterized by protection from diarrhea and growth faltering.

Results

Five hundred children were enrolled within the first week of birth, and of these 392 completed three years of observation. Stool samples were collected monthly and at the time of diarrhea. Successful sample collection and qPCR testing was completed for 96% of monthly surveillance time points and for 84% of the diarrheal cases (Figs 1 and S1 and Table 1). There were 1336 Cryptosporidium positive samples for analysis by year 3 (Fig 1). PCR- positive samples were classified as a separate infection if occurring greater than 65 days after the preceding positive sample [13]. The Cryptosporidium infection phenotype (diarrheal or sub-clinical) was based upon symptoms at the time of detection of the first Cryptosporidium - positive stool sample. Six hundred and ninety eight events met the definition of separate Cryptosporidium infections in the 392 children (Table 1).

Fig 1. COHORT diagram.

Fig 1

Study subjects, collected samples and new infection numbers. Abbreviations: RT-qPCR Real-Time quantitative polymerase chain reaction; DS: Diarrheal Stool samples; FU: Follow-up; MS: Monthly Stool Samples, Cq: Cycle Quantification.

Table 1. Frequency of Diarrheal Cryptosporidiosis in Repeated Infections.

Cryptosporidium Infection Number of infections Age in days Infection phenotype* Diarrhea Frequency**
Mean ± SD Range Diarrhea Sub-clinical Mean Upper limit Lower limit
1st 343 519 ± 250 [15-1088] 96 247 0.28 0.33 0.23
2nd 222 758 ± 209 [273-1079] 46 176 0.21 0.27 0.16
3rd 101 892 ±155 [399-1084] 17 84 0.17 0.26 0.10
4th 28 939± 129 [639-1095] 6 22 0.21 0.41 0.08
5th 3 994 ± 72.5 [929-1072] 0 3 0.0 0.70 0
6th 1 1067 1067 0 1 0.0 0.97 0

*Chi Square test for trend p = 0.011

** The frequency of Cryptosporidium associated diarrhea and range of values \by Chi Square test

Of the 698 infections experienced by the 392 infants retained in the study at 3 years of age, 167 were diarrheal and 531 sub-clinical cryptosporidiosis (Table 1). The Cq (cycle of quantification) value of the stool sample in which the parasite was first detected was used as an index of parasite burden.

The slopes derived from the GEE models for sub-clinical (1.9 ± 0.2) and diarrheal (1.49 ± 0.31) infections were not significantly different from each other (S2 Fig). However recurrent infections had as expected a lower amount or burden of Cryptosporidium than did the first infection (slope -1.85 ± 0.21; p<0.0001) (Fig 2A) To investigate if a reduction in the severity of clinical disease in recurrent infections could be correlated with the reduced parasite burden, the amount of sub-clinical and diarrheal disease in recurrent infections was investigated (Table 2).

Fig 2. Parasite burden was lower in recurrent infections.

Fig 2

A) Correlation between parasite burden and the number of Cryptosporidium infections. Each symbol represents the first detectable sample of an individual infection. Y-axis represents the quantitative cycle (Cq) of the diagnostic pan-Cryptosporidium PCR assay. X-axis shows the number of Cryptosporidium infections that had occurred in this child. The line represents the slope (-1.85 ± 0.21) and Y-intercept (26.95 ± 0.44) estimated from the GEE model with the exchangeable correlation structure (p<0.0001). B) Comparison of single infections (black symbol) with those that are part of a series (gray symbol). Bar graph (indicating data mean ± standard deviation) with individual data points. Each symbol on the box plot represents the first positive sample of an individual infection. X-axis refers to Infection number and, if the first infection, whether a second Cryptosporidium infection took place in the 3 years of life. Y-axis represents the quantitative cycle (Cq) of the diagnostic pan-Cryptosporidium PCR assay. Horizontal bars represent the result of a non-parametric Kruskal-Wallis test **** indicates p<0.0001.

Table 2. Distribution and Clinical Characterization of repeated Cryptosporidium infections.

# of Infections # of Children Cryptosporidium infections Total # of infections
1st 2nd 3rd 4th 5th 6th
DS* MS** DS MS DS MS DS MS DS MS DS MS
0 49 0 0 0 0 0 0 0 0 0 0 0 0 0
1 121 28 93 0 0 0 0 0 0 0 0 0 0 121
2 121 34 87 19 102 0 0 0 0 0 0 0 0 242
3 73 24 49 19 54 15 58 0 0 0 0 0 0 219
4 25 8 17 7 18 1 24 6 19 0 0 0 0 100
5 2 1 1 1 1 1 1 0 2 0 2 0 0 10
6 1 1 0 0 1 0 1 0 1 0 1 0 1 6
Total 392 96 247 46 176 17 84 6 22 0 3 0 1 698

To investigate if an initial high burden infection provided better protection against future infections with the Cryptosporidium parasite, we compared the Cq values of the infections in children who only had one infection in the first three years of life vs the Cq values of the first infection in children that had repeated infections (Fig 2B). The mean Cq values were similar in both cases (single infections: Cq 27.6 ± 5.4: 1st infection of multiples: 28.8 ± 6.0) and significantly lower than that in subsequent second infections where infections were >1 (Cq second infection: 31.5 ± 4.9).

We next evaluated if the lower parasite burden in repeat infections was influenced by the age of the children. As most recurrent Cryptosporidium infections occurred in older children, (Table 1) we analyzed a subset of the Cryptosporidium positive samples corresponding to the first to fifth infections in children aged between 2.25 and 2.75 years. The parasite burden measured by qPCR remained significantly lower in the recurrent infections (Fig 3). The negative relationship of lower parasite burden with repeated infections was not an artefact of PCR inhibitors in the stool of older children because detection of the Phocine herpesvirus (PhHV) DNA included as internal extraction control [27] was not significantly affected by the number of prior Cryptosporidium infections. We concluded that repeat infections had a lower parasite burden.

Fig 3. Parasite burden in older children.

Fig 3

The amount of parasite in stool was determined as a function of the number of Cryptosporidium infections in a child by linear regression. The analysis was restricted to children between 2.25 and 2.75 years of age (n=140). Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis, the number Cryptosporidium infections that had occurred in each child. Slope: -1.65, R squared value: 0.01125, Significance p<0.0001.

The duration of diarrheal disease was similar in the first infection and later reinfections (single infection: 4.8 ± 2.9 days; primary infection: 5.5 ± 3.9 days; later infections: 5.2 ± 3.6 days), however, the proportion of the diarrhea-associated Cryptosporidium infections decreased in the recurrent infections (Chi-squared test for trend p = 0.011) (Table 1). We concluded that the repeated Cryptosporidium infections were more likely to be sub-clinical.

Cryptosporidium and growth faltering

Growth faltering (low height for age; HAZ score) was analyzed from the 3 year old children based on the number of Cryptosporidium spp. infections [0–3 years] (both diarrhea and sub-clinical) (Table 2 and S3 and S4 Figs). The association between cryptosporidiosis and HAZ score at three years was examined by multiple regression in order to account for the effect of the confounding variables previously identified (Table 3) [13].

Table 3. Regression Analysis using selected predictors to test the association of Cryptosporidiosis with Height-for-Age Scores at 3 Years.

Parameter Effect (95% Confidence Interval) P Value
Cryptosporidium Infections -0.12 (-0.197, -0.043) 0.0024
Child LAZ at Birth 0.252 (0.159, 0.345) <0.0001
Maternal Weight 0.017 (0.007, 0.027) 0.0011
Maternal Height 0.037 (0.018, 0.055) <0.0001
Maternal Education 0.237 (0.027, 0.448) 0.0273
Household income 0.001 (0.000, 0.002) 0.1527
Treated water 0.163 (-0.045, 0.371) 0.1234

Cryptosporidium infection was negatively associated with the HAZ score at 3 years after adjusting for birth length-for-age (LAZ) score and maternal weight and education: each Cryptosporidium infection reoccurrence resulted in a decrease in HAZ score (Δ 0.12) at 3 years (Table 3). No significant relation was found between malnutrition at birth (LAZ score) and total number of Cryptosporidium infections during the follow-up (Fig 4A). However, the total number of Cryptosporidium infections was negatively associated with HAZ score at 3 years (Fig 4B, regression coef=-0.152, p = 0.0004) The association between HAZ and Cryptosporidium spp. infections was unaffected by whether the event was a sub-clinical infection or diarrheal disease (S5 Fig).

Fig 4. Cryptosporidiosis frequency was associated with growth faltering distinct from the impact of birth nutritional status.

Fig 4

A) Relationship between length for age z score (LAZ) at birth (Y-axis) and the total number of Cryptosporidium spp. infections (X-axis). The slope was not significantly different from one. B) Relationship between height for age z score (HAZ) at 3 years (Y-axis) and the total number of Cryptosporidium spp. infections (X-axis). This was initially analyzed by use of linear regression Slope: -0.152 ± 0.0429, R squared value: 0.0313, Significance p = 0.0004 and the relationship between the two data sets was then confirmed by the Pearsons correlation coefficient as described in the text. Children were defined to be at risk for growth faltering with a LAZ or HAZ score <-1 and malnourished at LAZ or HAZ score <-2. Orange box: birth LAZ or 3 year HAZ score -1 to -2; red box: birth LAZ or 3 year HAZ or score < -2.

Other measurements that are used as indicators of malnutrition were also significantly associated with the number of Cryptosporidium infections. These included mid-upper arm circumference (MUAC) (S6A Fig; MUACZ vs. number of Cryptosporidium infections slope: -0.088; p = 0.0123 and weight-for-age (WAZ score) (S6B Fig) (linear regression analysis slope: -0.115 p = 0.0093). However, neither BAZ (body-mass- for- age) (S6C Fig), used to measure acute protein-energy malnutrition or wasting (WHZ) were affected by a history of Cryptosporidium infections (S6D Fig).

The Pearson correlations among the number of Cryptosporidium infections, LAZ at birth, diarrheal episodes and HAZ at year 3 confirmed the results of the linear regression analysis (Cryptosporidium infections: HAZ at year 3: coef = -0.18, p = 0.024; Cryptosporidium infections: diarrheal episodes captured (all causes): coef = 0.22, p<0.0001; HAZ at year 3: LAZ at birth: coef = 0.28, p= 0.008). As expected, a significant correlation existed between LAZ at birth and HAZ at year 3 (simple linear regression p<0.0001 Fig 5A).

Fig 5. Correlates of cryptosporidiosis-associated growth-faltering.

Fig 5

A) Comparison of three year-HAZ with birth LAZ. (Slope: -0.294 ± 0.05; R squared value: 0.08; Significance p < 0.0001). B) Relationship of all-cause diarrhea with HAZ at 3 years of age (p = NS).

Enteric pathogens are endemic in the Bangladesh study population [28] and as a consequence, infants enrolled in the study cohort had repeated diarrheal episodes of which only some were associated with infection with the Cryptosporidium parasite. However, while Cryptosporidium infections (diarrheal and sub-clinical) were significantly associated with child HAZ at year 3 (Pearson’s correlation p = 0.0004), the number of all-cause diarrheal episodes was not (Fig 5B and Tables 3 and S1). This result supported our conclusion that this growth shortfall was specifically associated with recurrent cryptosporidiosis.

Mucosal IgA against the sporozoite Cp23 protein was associated with protection from growth faltering

Children with high levels of fecal anti-Cp23 IgA were regarded as being previously exposed to the Cryptosporidium parasite even if the parasite had been missed during surveillance for sub-clinical infections. In previous work it was shown that even if Cryptosporidium DNA had not been identified high levels (> mean value) of fecal anti-Cp23 IgA at one year of age was associated with an increased resistance to cryptosporidiosis through age three [14,20]. In children with high fecal anti-Cp23 IgA there was an increase in the number of days until a child was reinfected and a subsequent decrease in the proportion of children in this group reinfected during years 2-3 (in children with high fecal anti-Cp23 IgA 77.8% were reinfected versus 92.2%)

Here we additionally discovered that children with high levels (upper 50th percentile) of fecal anti-Cp23 IgA at one year of age were protected from growth faltering through year 3 (Fig 6). Antibodies against Cp23 are not however always developed in response to a Cryptosporidium infection. In addition to the analysis shown in Fig 6 the data was reexamined to determine if children exposed to the parasite but who did not have an antigenic response experienced less growth faltering after a Cryptosporidium infection than immunologically naive children. In S7 Fig the children were subgrouped into children who had been not exposed to the parasite, infected but had not developed a strong IgA response (as determined by the detection of Cryptosporidium DNA by qPCR) (representative examples S8A, S8B and S8C Fig), uninfected <365 days (representative example S8D Fig) or children who had high levels of IgA (representative examples S8E and S8F Fig). There was no difference between the birth LAZ of these different groups. Children infected with the Cryptosporidium parasite but who had low levels of fecal anti-Cp23 IgA had lower HAZ scores than children with high levels of fecal anti-Cp23 IgA (S7A Fig). The same result was obtained if the analysis was performed using the fecal IgA antibodies against a second sporozoite peptide (Cp17) to define the subgroups (S7B Fig).

Fig 6. High anti-Cp23 IgA levels were associated with a reduction in cryptosporidiosis-associated growth-faltering.

Fig 6

The HAZ values of children in the upper and lower 50th percentile for fecal IgA anti-Cp23 year were analyzed. HAZ are shown for children in both year one and year three of life. Mean ± standard deviation with individual data points. Horizontal bars represent the result of a non-parametric Kruskal-Wallis test ***p<0.001, **p<0.01.

Discussion

The key finding of this paper is that naturally acquired immunity protects from Cryptosporidium diarrhea but does not provide sterilizing immunity. The importance of this observation is two-fold: first it indicates that transmission likely occurs in semi-immune populations; and second that continued sub-clinical infections increase the risk of infection-related growth faltering. Encouragingly however, acquired immunity associated with high levels of mucosal IgA against the Cp23 cryptosporidium sporozoite antigen were associated with protection from malnutrition.

Many previous studies on cryptosporidiosis have focused on the health impact of diarrhea-associated cryptosporidiosis [7,12,2932]. However sub-clinical disease, as opposed to infection accompanied by diarrhea, may also have long term effects on child health. The link between sub-clinical cryptosporidiosis and malnutrition is now well known if not yet well understood [8,9,13,30]. In a recent study the global prevalence of cryptosporidiosis in people without diarrheal symptoms was 4.4% (95% confidence interval 2.9–6.3)[33]. During the 3 years of this study 212 children (54%) had only sub-clinical Cryptosporidium infections. This longitudinal study allowed us to take an in depth look at the role of sub-clinical reinfections in the exacerbation of growth faltering [13,21,24].

Anthropometric measurements are reliable non-invasive methods to monitor child malnutrition. The most commonly used metrics are a shortfall in child growth (low height for age: HAZ score) a consequence of chronic undernutrition and wasting (exemplified by a low weight for height: WHZ score). In line with most studies our results show that a history of cryptosporidiosis was associated with a decrease in the HAZ score of children irrespective of infection severity [8,25,34,35]. Here we found that child growth was negatively impacted not only by the first episode of cryptosporidiosis, but both occurred and remained constant in succeeding infections, even though parasite burden and diarrheal disease decreased. This study has, therefore, shown that naturally acquired partial immunity was not effective at preventing growth faltering and that a control strategy focused on only preventing diarrheal cryptosporidiosis may not prevent the stunted growth associated with cryptosporidiosis.

A limitation of the current study is that it was not possible to unambiguously attribute an episode of diarrhea to Cryptosporidium because children in this community were infected with multiple enteropathogens at the same time [25,28]. To mitigate the problem of correctly identifying Cryptosporidium-associated diarrheal infections these were defined as an episode of diarrhea accompanied by a new Cryptosporidium infection (i.e. the immediately preceding surveillance or diarrheal stool sample was negative for Cryptosporidium) [13]. A second limitation was that surveillance stool samples were collected at only monthly intervals which likely missed some subclinical infections, potentially underestimating the impact of cryptosporidiosis on child growth. The study however had notable strengths including most importantly its longitudinal design that combined collection of surveillance and clinical specimens with studies on child growth faltering.

The association of mucosal immunity to Cp23 with protection from growth faltering offers hope that a cryptosporidiosis vaccine could have a measurable impact on child health, even in the absence of absolute protection from infection.

Methods

Ethics statement

The study was approved by the Ethical and Research Review Committees of the International Centre for Diarrhoeal Disease Research, Bangladesh (PR-13092) and by the Institutional Review Board of the University of Virginia (IRB#20388). Informed written consent was obtained from the parents or guardians for the participation of the subjects in the study.

Child cohort

A total of 500 children were enrolled within one week of birth in an urban slum of Dhaka, Bangladesh beginning in June 2014 through March 2016 and were monitored for diarrheal diseases through bi-weekly home visits by trained field investigators. A monthly stool sample was also collected to evaluate asymptomatic infection and growth was measured every 3 months (“Cryptosporidiosis and Enteropathogens in Bangladesh”; ClinicalTrials.gov identifier NCT02764918). This area (Section 11 of Mirpur Thana) is densely populated with participants in this study having an average of 5.5 people living in 1.6 rooms. Annual median household income of participants was 14,000 Taka or approximately US $164 (Table 4). Anthropometric data was collected as previously described [13]. Each child was weighed on an electronic scale (kilograms, measured with electronic scale; TANITA, HD-314). Child height or length (depending on age) and mid-upper arm circumference were measured to the nearest 0.1 cm using a measuring board and plastic tape (Table 5). The height-for-age z score (HAZ); weight for age z score (WAZ); weight for height (WHZ); body mass index for age (BAZ); and mid-upper arm circumference for age (MUACZ) were calculated using the World Health Organization Anthro software (version 3.2.2) [13]. Children who had a HAZ score <-1 were defined as ‘at risk for malnutrition’ and HAZ < -2 as malnourished [26,36]. Diarrhea was defined as ≥3 loose stools within a 24-hour period as reported by the child’s caregiver with episodes separated by a gap of at least 3 days. This paper reports the data from 392 infants who were followed through three years of age.

Table 4. Maternal and family demographics.

Maternal and Family Characteristics N=392
Mean Maternal Age, year (SD) 24.63 (4.68)
Mean Maternal Weight, Kg (SD) 51.82 (10.17)
Mean Maternal Height, Cm (SD) 149.71 (5.03)
Mean Maternal BMI, kg/m2 (SD) 23.10 (4.32)
No Maternal Education, N (%) 87 (22.2)
Median Household income (BDT*) (IQR) 14,000 (10,000)
Treated water (Boil), N (%) 390 (74.0)

Abbreviations: SD, Standard Deviation; BDT, Bangladesh Taka; IQR, Inter Quartile Range

*1000 BDT is approximately 12 US dollars

Table 5. Infant demographic characteristics.

Infant Demographic Characteristics Year 2 N = 421 Year 3 N = 392
Gender, Female N (%) 229 (54.4) 214 (54.6)
Mean Infant Age in days, Range 733 (719–783) 1099 (1035–1134)
Mean Weight, Kg, (SD) 10.17 (1.31) 11.93 (1.52)
Mean Height, Cm, (SD) 81.72 (3.18) 89.78 (3.74)
Mean MUAC, Cm, (SD) 14.87 (1.02) 15.3 (1.00)
Mean WAZ, (SD) -1.34 (1.05) -1.42 (0.99)
Mean HAZ, (SD) -1.56 (0.98) -1.54 (0.98)
Mean MUACZ, (SD) -0.15 (0.85) -0.34 (0.79)
Mean BAZ, (SD) -0.52 (0.98) -0.63 (0.91)

Abbreviations: SD, Standard Deviation, MUAC, Mid Upper Arm Circumference, WAZ, Weight-for-age, HAZ, Height-for-age, MUACZ, Mid Upper Arm Circumference-for-age, BAZ, body mass index-for-age

Sampling and specimen testing

Fresh stool samples collected in the field were placed on ice and then brought to the lab on the same day and frozen within 6 h of collection (S1 Fig). Stool specimens were collected from children every month (monthly surveillance) and during episodes of diarrhea. A modified Qiagen stool DNA extraction protocol with 95°C incubation and a 3-minutes bead–beating step was used to extract DNA [13] (S9 Fig). These samples were tested with a multiplex qPCR assay which utilizes pan-Cryptosporidium primers and probes targeting the 18S rDNA gene and primers and probes to detect the Phocine herpesvirus (PhHV) extraction control (obtained from the European Virus Archive Global organization) as previously described (S10 Fig). All samples with a cycle threshold of ≤ 40 for cryptosporidium were used in this analysis [13]. In year 3 the diagnostic qPCR assay was not able to be completed on 0.9% of the collected diarrheal and 4.6% of the monthly surveillance samples (S2 Table).

Infection with Cryptosporidium was defined as detection of Cryptosporidium DNA by qPCR from stool. PCR- positive samples were classified as a separate infection if occurring greater than 65 days after the preceding positive sample [13]. The Cryptosporidium infection phenotype (diarrheal or sub-clinical) was based upon symptoms at the time of detection of the first Cryptosporidium - positive stool sample, whether diarrheal stool or monthly surveillance.

Statistical analysis

Descriptive statistics were expressed in mean ± standard deviation for continuous variables and as frequencies and proportions for categorical variables. The frequency of repeated Cryptosporidium infections in the first 3 years of life was summarized for diarrhea and sub-clinical infections separately and their differences were evaluated with the χ2 test. To account for within-child correlations among repeated Cryptosporidium infections, the relationship between parasite burden and the number of repeated Cryptosporidium infections was evaluated using the Generalized Estimating Equation (GEE) for repeated measurements, assuming an exchangeable correlation structure. Pearson correlation was calculated for univariate association of individual predictors with HAZ at 3 years. Since confounders such as LAZ at birth, maternal weight and height, maternal education, household income and access to treated water were previously shown to impact HAZ [8,13], a multivariable linear regression was performed to evaluate the association between Cryptosporidium infection and HAZ at 3 years after adjusting for these factors (Table 3). Similarly, a multiple regression analysis was performed to independently evaluate whether the number of episodes of diarrhea, irrespective of the causative pathogen, was associated with HAZ at 3 years. Analyses were performed using both the GraphPad Prism version 8.4.3 for Mac, (GraphPad Software, San Diego, California USA,), SAS 9.4 (Raleigh, NC) and R version 3.3.3, 32-bit.

Supporting information

S1 Table. Multivariable analysis of total all cause diarrhea and HAZ at year 3.

(TIF)

S2 Table. Symptomatic and asymptomatic samples collected during year 3.

(TIF)

S1 Fig. Flow chart of stool processing and molecular testing.

(TIF)

S2 Fig. Parasite Burden in diarrheal and sub-clinical infections.

Relationship between Parasite Burden and the number of recurrent Cryptosporidium infections. Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis, the total number of Cryptosporidium infections. The infection was designated as either diarrheal (red) or sub-clinical (green) based on the current infection phenotype. The data from diarrheal cases was offset to improve data visualization. To account for within-child correlations among repeated Cryptosporidium infections, the generalized estimating equation (GEE) method for repeated measurements were used with exchangeable correlation structure. As the intercept of the diarrheal and sub-clinical models was not statistically different the common intercept (27.02 ± 0.45) was used. The slope of the data derived from the sub-clinical (1.9 ± 0.2) and diarrheal (1.49 ± 0.31) exchangeable models were not significantly different from each other (p = 0.071) although both were statistically different from zero (p<0.0001).

(TIF)

S3 Fig. Distribution of repeated Cryptosporidium infections.

x axis child age in months; left y-axis child HAZ scores; right y-axis frequency of Cryptosporidium (diarrheal and sub-clinical) infections (shown as the number that occurred per the age of the child in months). All graphs include as a reference the HAZ score of children where no Cryptosporidium infections were detected (green circle and line). Cryptosporidium infections: Light blue triangle dotted blue connection line: infection one; purple circle and dotted line: infection two; light red square and dotted line: infection three; black triangle and dotted line: infection four A) blue symbol and solid line HAZ score of children who had one Cryptosporidium infections by 3 years of age B) purple square and solid line HAZ score of children who had two Cryptosporidium infections by three years of age C) red square and solid line HAZ score of children who had three Cryptosporidium infections by three years of age D) black square and solid line HAZ score of children who had four Cryptosporidium infections by three years of age.

(TIF)

S4 Fig. Recurrent cryptosporidiosis results in greater growth faltering Each symbol represents a single child.

Box plot comparing the height for age z score at 3 years (HAZ) (Y-axis) mean and standard deviation shown Children were considered to be at Risk for malnutrition is they have a HAZ score <-1 and malnourished at HAZ-2: orange box: 3-year HAZ score -1 to -2; red box 3-year HAZ score < -2. X-axis Number of Cryptosporidium infections. Bar indicates the result of a non-parametric Kruskal-Wallis test for multiple comparisons * indicates p<0.05 ** indicates p<0.01.

(TIF)

S5 Fig. Comparison of Cryptosporidiosis associated Growth-faltering in diarrheal and sub-clinical infections.

Graphs show results from a simple linear regression with each symbol representing a single child. Black symbols represent children who were never infected or had sub-clinical infections. The blue symbols indicate children who have had one or more than one episodes of diarrhea- associated cryptosporidiosis. Height for age (HAZ) z score at 3 years is shown on the Y-axis. The slope of the diarrheal-associated and sub-clinical groups are identical. Pooled Slope: -0.1545. Children are considered to be at Risk for malnutrition if they have a HAZ score <-1 and malnourished at HAZ -2: orange box: 3-year HAZ score -1 to -2; red box: 3-year HAZ score < -2. X-axis indicates number of Cryptosporidium infections.

(TIF)

S6 Fig. Cryptosporidiosis was associated with chronic but not acute malnutrition at year 3.

Graphs show results from a simple linear regression with each symbol representing a single child X-axis indicates number of Cryptosporidium infections A) Y-axis MUACZ circumference of the mid-upper arm (muscle wasting) B) Y-axis WHZ score (low weight for height (wasting) a measure of acute malnutrition C) Y axis WAZ score (low weight for age) a measure of acute and chronic malnutrition and D) BAZ (body mass index for age).

(TIF)

S7 Fig. Low anti-Cryptosporidium IgA levels after an infection were associated with a subsequent increase in cryptosporidiosis-associated growth-faltering.

(TIF)

S8 Fig. Parasite Burden in Reperesentative children.

Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis age of child in days A-C Infants with high fecal IgA anti-Cryptosporidium at year one D-F Infants with low fecal IgA anti-Cryptosporidium at year one G).

(TIF)

S9 Fig. Flow chart of stool TNA extraction procedure using QIAamp Fast DNA Stool Mini Kit from fresh or frozen stool samples.

(TIF)

S10 Fig. Flow chart of Multiplex qPCR of Cryptosporidium, Giardia, Entameoba histolytica by targeting the18S gene.

(TIF)

Acknowledgments

We are grateful for the participation of the parents and children in this study as well as the staff of the Emerging Infectious Diseases Division of icddr,b for contributing to this research. The governments of Bangladesh, Canada, Sweden, and the UK provide core support to icddr,b.

Data Availability

Select clinical metadata is available on the NCBI’s dbGaP under accession number phs001665.v2.p1. The data for this study is collected as a sub-study of dbGaP phs001475.v2.p1.

Funding Statement

This work was supported by grants NIH R01-043596 to WP and CG, R21-142656 to CG and the Bill & Melinda Gates Foundation OPP1100514 to WP. The funders had no role in study design, data collection and analysis or decision to submit for publication.

References

  • 1.Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. The Burden of Cryptosporidium Diarrheal Disease among Children &lt; 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). Kosek M, editor. PLoS Negl Trop Dis. 2016;10: e0004729. doi: 10.1371/journal.pntd.0004729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wang H, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390: 1084–1150. doi: 10.1016/S0140-6736(17)31833-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Korpe PS, Valencia C, Haque R, Mahfuz M, McGrath M, Houpt E, et al. Epidemiology and Risk Factors for Cryptosporidiosis in Children from Eight Low-income Sites: Results from the MAL-ED Study. Clin Infect Dis. 2018; doi: 10.1093/cid/ciy355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Haque R, Mondal D, Karim A, Molla IH, Rahim A, Faruque ASG, et al. Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis. 2009;48: 1191–1197. doi: 10.1086/597580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cama V a, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, et al. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J Infect Dis. 2007;196: 684–91. doi: 10.1086/519842 [DOI] [PubMed] [Google Scholar]
  • 6.Chalmers RM, Davies AP, Tyler K. Cryptosporidium. Microbiol (United Kingdom). 2019;165: 500–502. doi: 10.1099/mic.0.000764 [DOI] [PubMed] [Google Scholar]
  • 7.Chavez MA, White AC. Novel treatment strategies and drugs in development for cryptosporidiosis. Expert Review of Anti-Infective Therapy. Taylor and Francis Ltd; 2018. pp. 655–661. doi: 10.1080/14787210.2018.1500457 [DOI] [PubMed] [Google Scholar]
  • 8.Korpe P, Haque R, Gilchrist CA, Valencia C, Niu F, Lu MM, et al. Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe Malnutrition. PLoS Negl Trop Dis. 2016;10: e0004564. doi: 10.1371/journal.pntd.0004564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kattula D, Jeyavelu N, Prabhakaran AD, Premkumar PS, Velusamy V, Venugopal S, et al. Natural History of Cryptosporidiosis in a Birth Cohort in Southern India. Clin Infect Dis. 2017;64: 347–354. doi: 10.1093/cid/ciw730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, et al. Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study. Lancet Glob Heal. 2018;6: e758–e768. doi: 10.1016/S2214-109X(18)30283-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Krumkamp R, Aldrich C, Maiga-Ascofare O, J M, Rakotozandrindrainy N, Borrmann S, et al. Transmission of Cryptosporidium spp. among human and animal local contact networks in sub-Saharan Africa: a multi-country study. Clin Infect Dis. 2020; ciaa223. Available: https://pubmed.ncbi.nlm.nih.gov/32150243/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Eibach D, Krumkamp R, Al-Emran HM, Sarpong N, Hagen RM, Adu-Sarkodie Y, et al. Molecular characterization of Cryptosporidium spp. among children in rural Ghana. PLoS Negl Trop Dis. 2015;9: e0003551. doi: 10.1371/journal.pntd.0003551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Steiner KL, Ahmed S, Gilchrist CA, Burkey C, Cook H, Ma JZ, et al. Species of Cryptosporidia Causing Subclinical Infection Associated With Growth Faltering in Rural and Urban Bangladesh: A Birth Cohort Study. Clin Infect Dis. 2018;67: 1347–1355. doi: 10.1093/cid/ciy310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Steiner KL, Kabir M, Hossain B, Gilchrist CA, Ma JZ, Ahmed T, et al. Delayed Time to Cryptosporidiosis in Bangladeshi Children is Associated with Greater Fecal IgA against Two Sporozoite-Expressed Antigens. Am J Trop Med Hyg. 2021;104: 229–232. doi: 10.4269/ajtmh.20-0657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Taniuchi M, Sobuz SU, Begum S, Platts-Mills JA, Liu J, Yang Z, et al. Etiology of Diarrhea in Bangladeshi Infants in the First Year of Life Using Molecular Methods. J Infect Dis. 2013;e-pub ahea: jit507-. doi: 10.1093/infdis/jit507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lemieux MW, Sonzogni-Desautels K, Ndao M. Lessons learned from protective immune responses to optimize vaccines against cryptosporidiosis [Internet]. Pathogens. MDPI AG; 2018. doi: 10.3390/pathogens7010002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sateriale A, Šlapeta J, Baptista R, Engiles JB, Gullicksrud JA, Herbert GT, et al. A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity. Cell Host Microbe. 2019;26: 135–146.e5. doi: 10.1016/j.chom.2019.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen X-MM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15: 85–94. doi: 10.1016/S1473-3099(14)70772-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tzipori S, Roberton D, Chapman C. Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum. Br Med J. 1986;293: 1276–7. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1342109&tool=pmcentrez&rendertype=abstract [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Steiner KL, Kabir M, Priest JW, Hossain B, Gilchrist CA, Cook H, et al. Fecal IgA against a sporozoite antigen at 12 months is associated with delayed time to subsequent cryptosporidiosis in urban Bangladesh: a prospective cohort study. Clin Infect Dis. 2020;70: 323–326. doi: 10.1093/cid/ciz430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ajjampur SSR, Sarkar R, Sankaran P, Kannan A, Menon VK, Muliyil J, et al. Symptomatic and asymptomatic Cryptosporidium infections in children in a semi-urban slum community in southern India. Am J Trop Med Hyg. 2010;83: 1110–5. doi: 10.4269/ajtmh.2010.09-0644 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Okhuysen PC, Chappell CL, Sterling CR, Jakubowski W, DuPont HL. Susceptibility and serologic response of healthy adults to reinfection with Cryptosporidium parvum. Infect Immun. 1998;66: 441–443. doi: 10.1128/IAI.66.2.441-443.1998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Guerrant DI, Moore SR, Lima AAM, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in apoor urban community in northeast Brazil. Am J Trop Med Hyg. 1999;61: 707–713. doi: 10.4269/ajtmh.1999.61.707 [DOI] [PubMed] [Google Scholar]
  • 24.Checkley W, Gilman RH, Epstein LD, Suarez M, Diaz JF, Cabrera L, et al. Asymptomatic and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am J Epidemiol. 1997;145: 156–63. doi: 10.1093/oxfordjournals.aje.a009086 [DOI] [PubMed] [Google Scholar]
  • 25.Schnee AE, Haque R, Taniuchi M, Uddin J, Alam M, Liu J, et al. Identification of etiology-specific diarrhea associated with linear growth faltering in Bangladeshi infants. Am J Epidemiol. 2018;187: 2210–2218. doi: 10.1093/aje/kwy106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.de Onis M, Branca F. Childhood stunting: A global perspective. Matern Child Nutr. 2016;12: 12–26. doi: 10.1111/mcn.12231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet. 2016;388: 1291–1301. doi: 10.1016/S0140-6736(16)31529-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Taniuchi M, Sobuz SU, Begum S, Platts-Mills JA, Liu J, Yang Z, et al. Etiology of diarrhea in Bangladeshi infants in the first year of life analyzed using molecular methods. J Infect Dis. 2013;208: 1794–802. doi: 10.1093/infdis/jit507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Platts-Mills JA, Liu J RE et al. Aetiology, burden and clinical characteristics of diarrhea in children in low-resource settings using quantitative molecular diagnostics: results from the MAL-ED cohort study. Lancet Glob Heal. 2018;in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cama VA, Bern C, Roberts J, Cabrera L, Sterling CR, Ortega Y, et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. Emerg Infect Dis. 2008;14: 1567–74. doi: 10.3201/eid1410.071273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chappell CL, Okhuysen PC, Langer-Curry RC, Akiyoshi DE, Widmer G, Tzipori S. Cryptosporidium meleagridis: Infectivity in healthy adult volunteers. Am J Trop Med Hyg. 2011;85: 238–242. doi: 10.4269/ajtmh.2011.10-0664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ajjampur SSR, Liakath FB, Kannan A, Rajendran P, Sarkar R, Moses PD, et al. Multisite study of cryptosporidiosis in children with diarrhea in India. J Clin Microbiol. 2010;48: 2075–81. doi: 10.1128/JCM.02509-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Dong S, Yang Y, Wang Y, Yang D, Yang Y, Shi Y, et al. Prevalence of Cryptosporidium Infection in the Global Population: A Systematic Review and Meta-analysis. Acta Parasitol. 2020; doi: 10.2478/s11686-020-00230-1 [DOI] [PubMed] [Google Scholar]
  • 34.Hossain MJ, Saha D, Antonio M, Nasrin D, Blackwelder WC, Ikumapayi UN, et al. Cryptosporidium infection in rural Gambian children: Epidemiology and risk factors. Bartelt LA, editor. PLoS Negl Trop Dis. 2019;13: e0007607. doi: 10.1371/journal.pntd.0007607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Bushen OY, Kohli A, Pinkerton RC, Dupnik K, Newman RD, Sears CL, et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of Cryptosporidium hominis and Cryptosporidium parvum. Trans R Soc Trop Med Hyg. 2007;101: 378–84. doi: 10.1016/j.trstmh.2006.06.005 [DOI] [PubMed] [Google Scholar]
  • 36.Guide I. Interpretation Guide. Nutr Landacape Inf Syst. 2012; 1–51. doi: 10.1159/000362780.Interpretation [DOI] [Google Scholar]

Decision Letter 0

Kami Kim

31 Mar 2021

Dear Dr. Petri, Jr.,

Thank you very much for submitting your manuscript "Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please pay particular attention to the comments from reviewer 3, who raises some important questions about the link between immunity and infections as well as parasite burden and outcomes. Please note that the journal has expanded its scope and welcomes manuscripts with a clinical focus, recognizing that studies in humans may by their nature be correlative rather than purely mechanistic. 

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Kami Kim

Section Editor

PLOS Pathogens

Kami Kim

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: This manuscript by Kabir and colleagues is focused on immunity to cryptosporidiosis in children. Methodologically this paper is somewhat outside the ‘typical’ PLoS Pathogens focus on lab-based studies that aim at molecular mechanism. However, the editor sent this for review, and thus likely made the decision that it is well within the scope of the journal. This manuscript is longitudinal observational study in a cohort of young children that grow up in an environment of very high likelihood of exposure to Cryptosporidium infection. From a public health perspective this is by far the most relevant group. Several studies including GEMS and MALED have previously shown significant correlation of cryptosporidiosis with diarrheal disease, malnutrition, stunting, and death. The introduction (and discussion) is rather brief on this important aspect and could provide more relevant background to the reader – in particular for this journal and audience. Also given the audience a bit more information on the biology of the pathogen may be helpful. Whether, and to which extend, humans develop immunity to this infection is an important and not fully settled question with obvious impact on the probability of vaccine success. This study addresses several important issues. The key finding is that while most children experience multiple infections the parasite and disease burden decreases significantly along the timeline which the authors interpret as non-sterile disease burden. Measurements of antibody titers are a reasonable independent correlate and support the main conclusion. The true value of the study lies in the size of the group of children, the excellent retention and the high frequency of measurements regardless, whether children showed signs of disease or not. This is a significant accomplishment and a unique resource to the field. The question whether kids gain resistance over time due to immunity or due to age, or age associated confounders like changes in food or microbiome, has been debated for some time. The study group here is of sufficient size to control for age and importantly finds the protective effect to be age independent. The study also uses a comparison of single infection to first in several as a clever way to control for overall differences in susceptibility to the infection. As other studies they find significant association between infection with malnutrition and growth faltering and their longitudinal data allow better treatment of some of the confounders, and importantly, they find that overt disease is not required to cause this. Interestingly, cryptosporidiosis (symptomatic or not) was a stronger predictor than all cause diarrheal disease. Overall, I read the paper with interest and found the main conclusions to be important and well supported and the discussion balanced. For the broader audience the discussion could have featured comparison to other infections. Rotavirus may be of particular interest here as for this virus, similar to what the authors describe for an apicomplexan here, immunity is non-sterile but associated with significant benefit. Also, discussion of the literature around the rotavirus vaccine may offer the authors opportunity to critically discuss the potential value of such prevention for cryptosporidiosis.

Reviewer #2: This manuscript reports the results of a birth cohort study that prospectively studied Cryptosporidium infection (by qPCR) both symptomatic and asymptomatic and nutrition. Overall, the study demonstrates immunity against diarrhea with repeat infections, but not sterile immunity. Also, there was a clear effect of both diarrhea and non-diarrheal infections on measures of chronic malnutrition in children. The authors also noted an association between a marked of immunity (fecal IgA versus Cp23) and protection from the nutritional effects of reinfection, despite the absence of sterile immunity. These are important observations and the data seem to be quite rigorous, though observational and not mechanistic.

Reviewer #3: This manuscript describes a well-designed birth cohort study to look at the effects of cryptosporidiosis and immunity to cryptosporidiosis on child development. The results show that as the number of repeat infections increase, there is less diarrhea associated with infection and a lower parasite burden (as determined by Cq values of the first positive sample of each infection). Growth faltering is worse as the number of repeat infections increase. The authors then show that high levels of fecal anti-Cp23 IgA in the first year of life is associated with protection from growth faltering through year 3. It is critical for the authors to highlight how their results add to previously published data on cryptosporidiosis, immunity to cryptosporidiosis, and growth faltering; most of what they report has been reported from other studies. The data as presented leaves many questions. For example, how do IgA levels relate to repeat infections? Presumably, immunity increases with repeat infections (suggested by lower parasite burdens and less diarrhea) but children with repeat infections have worse outcomes. Do the children with high IgA in Figure 6 (Group 1) also have fewer infections? What is the parasite burden for each child over the 3 years? Does this correlate with outcomes?

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response)

Reviewer #2: None

Reviewer #3: The authors state in the discussion that “The key finding of this paper is that naturally acquired immunity protects from Cryptosporidium diarrhea but does not provide sterilizing immunity”, but the results do not show that increased immunity leads to less diarrhea-all that is shown is that increased immunity leads to less growth faltering. Can the relationship between IgA levels and repeat infections be analyzed and described?

In the analysis of the samples, parasite burden has been quantified by qPCR, but only the Cq of the first positive sample is used in the analysis. Is there any way to use the qPCR results to estimate total parasite burden over the 3 years?

It is not stated in the methods the timing of sample collection during diarrheal episodes-were diarrheal samples collected and tested daily? Is it possible to quantify parasite burden of a diarrheal episode by area under the curve analysis?

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: Minor comments and corrects:

The introduction is rather brief.

The authors might briefly specify the definition of a repeat infection in the results section (it is well described in the M&M) as this is an important feature of the experimental set up.

The investigators use value of the first detectable sample as the ‘amplitude’ of burden. Why did they do that and not something like area under the curve?

I feel it may help the reader to understand this infection and the study design and results better, to see several ‘representative’ children over the entire time with all samples, essentially cv burden curves over the three years highlighting examples of the ‘epidemiological phenotypes’ they discuss later. Either in fig. 1 or as a supplementary figure.

L58 cut ‘were’

Reviewer #2: Table 2. This table is not very clear and overall distracts from the points. I think the manuscript would be stronger with it deleted.

Fig 3 and Fig S4. Some of the. points noted have a cQ of 40, which barely meets the case definition. Please check that these were in fact positive.

Fig 5. This figure duplicates data in the top and bottom half of the figure. Both are not needed.

Fig 6 would be clearer if labeled IgA high and low rather than group 1 and 2.

Reviewer #3: Fig 1: please clarify “within 65 days of previous”

Table 2 does not show Cq values, but the way the text is worded in lines 93-94 makes it sound like the table does have Cq values. Please re-word to make the text clearer.

In many figures the mean and error bars cannot be seen (ie, Fig 2B, Fig S6 and Fig 6). Please use a different color for the bars.

Fig 5A. Is the bar to the right of the table supposed to be color coded?

Figure S5 A-D need to be enlarged.

Line 162-Should the referral to Table 5 be instead a referral to Figure S5?

In lines 186-187 the text states the Pearson coefficient and p value for the Cryptosporidium infections: HAZ at year 3 comparison as: coef = -0.18, p=0.024. But in lines 193 to 195 the text states: ”However, while Cryptosporidium infections (diarrheal and sub-clinical) were significantly associated with child HAZ at year 3 (Pearson’s correlation p=0.0004). These statements seem to report different p values for the same comparison. Please clarify.

Line 196: Should say Table S2.

Lines 211-214 and Figure S9A. Can you please clarify the reason why Group 2 at year 1 is split out into uninfected (2a) and pcr+ (2b) children? What does “diagnostic qPCR positive only” mean? It is unclear what children are included in group 2b. Was infection diagnosed by other methods?

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 1

Kami Kim

16 May 2021

Dear Dr. Petri, Jr.,

We are pleased to inform you that your manuscript 'Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kami Kim

Section Editor

PLOS Pathogens

Kami Kim

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Kami Kim

21 Jun 2021

Dear Dr. Petri, Jr.,

We are delighted to inform you that your manuscript, "Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Multivariable analysis of total all cause diarrhea and HAZ at year 3.

    (TIF)

    S2 Table. Symptomatic and asymptomatic samples collected during year 3.

    (TIF)

    S1 Fig. Flow chart of stool processing and molecular testing.

    (TIF)

    S2 Fig. Parasite Burden in diarrheal and sub-clinical infections.

    Relationship between Parasite Burden and the number of recurrent Cryptosporidium infections. Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis, the total number of Cryptosporidium infections. The infection was designated as either diarrheal (red) or sub-clinical (green) based on the current infection phenotype. The data from diarrheal cases was offset to improve data visualization. To account for within-child correlations among repeated Cryptosporidium infections, the generalized estimating equation (GEE) method for repeated measurements were used with exchangeable correlation structure. As the intercept of the diarrheal and sub-clinical models was not statistically different the common intercept (27.02 ± 0.45) was used. The slope of the data derived from the sub-clinical (1.9 ± 0.2) and diarrheal (1.49 ± 0.31) exchangeable models were not significantly different from each other (p = 0.071) although both were statistically different from zero (p<0.0001).

    (TIF)

    S3 Fig. Distribution of repeated Cryptosporidium infections.

    x axis child age in months; left y-axis child HAZ scores; right y-axis frequency of Cryptosporidium (diarrheal and sub-clinical) infections (shown as the number that occurred per the age of the child in months). All graphs include as a reference the HAZ score of children where no Cryptosporidium infections were detected (green circle and line). Cryptosporidium infections: Light blue triangle dotted blue connection line: infection one; purple circle and dotted line: infection two; light red square and dotted line: infection three; black triangle and dotted line: infection four A) blue symbol and solid line HAZ score of children who had one Cryptosporidium infections by 3 years of age B) purple square and solid line HAZ score of children who had two Cryptosporidium infections by three years of age C) red square and solid line HAZ score of children who had three Cryptosporidium infections by three years of age D) black square and solid line HAZ score of children who had four Cryptosporidium infections by three years of age.

    (TIF)

    S4 Fig. Recurrent cryptosporidiosis results in greater growth faltering Each symbol represents a single child.

    Box plot comparing the height for age z score at 3 years (HAZ) (Y-axis) mean and standard deviation shown Children were considered to be at Risk for malnutrition is they have a HAZ score <-1 and malnourished at HAZ-2: orange box: 3-year HAZ score -1 to -2; red box 3-year HAZ score < -2. X-axis Number of Cryptosporidium infections. Bar indicates the result of a non-parametric Kruskal-Wallis test for multiple comparisons * indicates p<0.05 ** indicates p<0.01.

    (TIF)

    S5 Fig. Comparison of Cryptosporidiosis associated Growth-faltering in diarrheal and sub-clinical infections.

    Graphs show results from a simple linear regression with each symbol representing a single child. Black symbols represent children who were never infected or had sub-clinical infections. The blue symbols indicate children who have had one or more than one episodes of diarrhea- associated cryptosporidiosis. Height for age (HAZ) z score at 3 years is shown on the Y-axis. The slope of the diarrheal-associated and sub-clinical groups are identical. Pooled Slope: -0.1545. Children are considered to be at Risk for malnutrition if they have a HAZ score <-1 and malnourished at HAZ -2: orange box: 3-year HAZ score -1 to -2; red box: 3-year HAZ score < -2. X-axis indicates number of Cryptosporidium infections.

    (TIF)

    S6 Fig. Cryptosporidiosis was associated with chronic but not acute malnutrition at year 3.

    Graphs show results from a simple linear regression with each symbol representing a single child X-axis indicates number of Cryptosporidium infections A) Y-axis MUACZ circumference of the mid-upper arm (muscle wasting) B) Y-axis WHZ score (low weight for height (wasting) a measure of acute malnutrition C) Y axis WAZ score (low weight for age) a measure of acute and chronic malnutrition and D) BAZ (body mass index for age).

    (TIF)

    S7 Fig. Low anti-Cryptosporidium IgA levels after an infection were associated with a subsequent increase in cryptosporidiosis-associated growth-faltering.

    (TIF)

    S8 Fig. Parasite Burden in Reperesentative children.

    Each symbol represents the first detectable sample of an individual infection. Y-axis, quantitative cycle of the diagnostic pan-Cryptosporidium PCR assay (Cq). X-axis age of child in days A-C Infants with high fecal IgA anti-Cryptosporidium at year one D-F Infants with low fecal IgA anti-Cryptosporidium at year one G).

    (TIF)

    S9 Fig. Flow chart of stool TNA extraction procedure using QIAamp Fast DNA Stool Mini Kit from fresh or frozen stool samples.

    (TIF)

    S10 Fig. Flow chart of Multiplex qPCR of Cryptosporidium, Giardia, Entameoba histolytica by targeting the18S gene.

    (TIF)

    Attachment

    Submitted filename: Response to Reviewer Comments_PPATHOGENS.docx

    Data Availability Statement

    Select clinical metadata is available on the NCBI’s dbGaP under accession number phs001665.v2.p1. The data for this study is collected as a sub-study of dbGaP phs001475.v2.p1.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES